XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
As disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, certain of our Section 16 officers and directors adopted Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K of the Exchange Act) during the quarter ended December 31, 2023. In addition to the plans disclosed in our Form 10-K, our director Fred B. Craves, Ph.D. also adopted a Rule 10b5-1 trading arrangement on December 15, 2023 for the sale of up to 52,489 shares of our common stock through August 31, 2024, which arrangement was inadvertently not disclosed in the Form 10-K.
The following table shows the number of shares of our common stock subject to the current Rule 10b5-1 trading arrangements of our Section 16 officers and directors in place as of May 3, 2024:

Name of Director or Section 16 Officer
Title of Director or Section 16 Officer
Date of Adoption, Modification, or Termination
Duration of the Plan
Aggregate Number of Shares of Common Stock that may be Sold under the Plan
Richard Levy, MD
Director
11/30/2023
June 16, 2025
15,000
Fred B. Craves, Ph.D.
Director
12/15/2023
August 31, 2024
52,489
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Richard Levy [Member]  
Trading Arrangements, by Individual  
Name Richard Levy, MD
Title Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date 11/30/2023
Arrangement Duration 564 days
Aggregate Available 15,000
Fred B. Craves [Member]  
Trading Arrangements, by Individual  
Name Fred B. Craves, Ph.D.
Title Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date 12/15/2023
Arrangement Duration 260 days
Aggregate Available 52,489